Page last updated: 2024-09-05

bn 80927 and camptothecin

bn 80927 has been researched along with camptothecin in 6 studies

*Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. [MeSH]

*Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. [MeSH]

Compound Research Comparison

Studies
(bn 80927)
Trials
(bn 80927)
Recent Studies (post-2010)
(bn 80927)
Studies
(camptothecin)
Trials
(camptothecin)
Recent Studies (post-2010) (camptothecin)
61113,0022,2295,391

Protein Interaction Comparison

ProteinTaxonomybn 80927 (IC50)camptothecin (IC50)
Histone deacetylase 3Homo sapiens (human)0.05
Multidrug resistance-associated protein 4Homo sapiens (human)7.4
DNA topoisomerase 1Homo sapiens (human)1.9799
Somatostatin receptor type 1Homo sapiens (human)0.0022
Somatostatin receptor type 2Homo sapiens (human)0.0022
Somatostatin receptor type 4Homo sapiens (human)0.0022
Somatostatin receptor type 3Homo sapiens (human)0.0022
Somatostatin receptor type 5Homo sapiens (human)0.0022
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.97
Histone deacetylase 4Homo sapiens (human)0.05
Histone deacetylase 1Homo sapiens (human)0.05
Histone deacetylase 7Homo sapiens (human)0.05
Histone deacetylase 2Homo sapiens (human)0.05
Polyamine deacetylase HDAC10Homo sapiens (human)0.05
Histone deacetylase 11 Homo sapiens (human)0.05
Histone deacetylase 8Homo sapiens (human)0.05
Histone deacetylase 6Homo sapiens (human)0.05
Histone deacetylase 9Homo sapiens (human)0.05
Histone deacetylase 5Homo sapiens (human)0.05

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bigg, DC; Coulomb, H; Demarquay, D; Harnett, J; Huchet, M; Lanco, C; Lavergne, O; Lesueur-Ginot, L; Rolland, A1
Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L1
Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O1
Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Prévost, G1
Yang, S; Zhang, WN1
Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF1

Reviews

1 review(s) available for bn 80927 and camptothecin

ArticleYear
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2004, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2004

Trials

1 trial(s) available for bn 80927 and camptothecin

ArticleYear
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome

2012

Other Studies

4 other study(ies) available for bn 80927 and camptothecin

ArticleYear
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
    Bioorganic & medicinal chemistry letters, 1999, Sep-06, Volume: 9, Issue:17

    Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured

1999
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2000
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000
BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Cancer research, 2004, Jul-15, Volume: 64, Issue:14

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays

2004